About the Project:
Moderna Therapeutics, founded in 2011, has experienced unprecedented growth in the clinical development of mRNA therapies for numerous diseases and vaccinations. In 2016, the company decided to embark upon its first cGMP manufacturing facility and selected Norwood, MA to be its site. Hereva was consulted during the site selection process and was retained by Moderna as owner’s representative to manage the programming, engineering and design of this state of the art drug substance processing and cGMP manufacturing facility.
Formerly a Polaroid plant, the 200,000 SF facility in Norwood will house all clinical manufacturing activities, from raw material production to active pharmaceutical ingredients (APIs), formulation, filling and finish. In addition to the cGMP manufacturing and warehouse areas, the building will house all associated quality and building infrastructure services, approximately 25,000 SF of collaborative, open plan office and an amenities hub that contains a cafeteria, fitness center, training and conference facilities, and numerous employee recreation and meeting areas.
Hereva has worked closely with Moderna to develop a facility that is state of the art and modern in its design, but is carefully tied to the community remaining in Cambridge. Key features of the design tie into Moderna’s branding and corporate identity, and high-tech AV systems will tie the site into other Moderna sites in Cambridge and beyond.
Moderna Norwood is expected to be occupied in Q2 2018 with fully functioning clinical operations not far behind. The project value exceeds $100M and hopes to realize LEED Gold Certification.
About the Client:
Moderna is pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching. It could transform not only how certain diseases are treated but also how medicines are discovered, developed and manufactured – at a breadth, scale and speed not common in the biopharma industry. Since foundation in 2011, they have built the industry’s leading mRNA technology platform, the infrastructure to accelerate drug discovery and speed early development, a rapidly expanding pipeline, and an unparalleled team.
To read more about this project: